top of page

Mass General Cancer Center Classical Hematology Review & ASH Highlights ~ Feb 14-15, 2023

Mass General Cancer Center Classical Hematology Review & ASH Highlights


February 14 - 15, 2023 | 12:00 - 3:45 PM ET

This event will take place virtually, via Zoom. Details provided upon registration.



Description The Mass General Cancer Center Classical Hematology Review and ASH Highlights will be an interactive, virtual CME program highlighting state-of-the-art care for patients with hematologic diseases. This is a unique course, focused solely on classical hematology and the intricacies that come along with these diseases. Presentations will provide a combination of consultative case studies, approaches to patient care with various abnormalities, and the latest science and treatment paradigms from the 2022 ASH Meeting. There will be designated time in each section for a moderated Q&A, encouraging interaction between the audience and faculty.


Agenda Tuesday, February 14, 2023

  • 12:00 PM Welcome | Annemarie Fogerty, MD

  • 12:05 Sickle Cell | Sharl Azar, MD

  • 12:35 Hereditary Hemorrhagic Telangiectasia (HHT) | Hanny Al-Samkari, MD

  • 12:55 Tranfusion Medicine Consultation | Sunny Dzik, MD

  • 1:25 Combined Q&A | Hanny Al-Samkari, MD, Sharl Azar, MD & Sunny Dzik, MD

  • 1:40 Break

  • 1:55 Iron Disorders (Iron Deficiency & Hemochromatosis) | Katayoon Goodarzi, MD

  • 2:10 Porphyria | Rebecca Karp, MD

  • 2:30 Combined Q&A | Katayoon Goodarzi, MD & Rebecca Karp, MD

  • 2:45 Neutropenia | David Sykes, MD, PhD

  • 3:05 Autoimmune Hemolysis | David Kuter, MD, DPhil

  • 3:35 Complement-Mediated Disorders | Anem Waheed, MD, MPH

  • 4:05 Combined Q&A | David Kuter, MD, DPhil, David Sykes, MD, PhD & Anem Waheed, MD, MPH

  • 4:15 PM Adjournment

Wednesday, February 15, 2023

  • 12:00 PM Welcome | Annemarie Fogerty, MD

  • 12:05 Thrombocytopenias | David Kuter, MD, DPhil

  • 12:35 Reproductive Hematology | Annemarie Fogerty, MD

  • 1:05 Combined Q&A | Annemarie Fogerty, MD & David Kuter, MD, DPhil

  • 1:20 Break

  • 1:35 Venous Thromboembolism (VTE) | Rachel Rosovsky, MD, MPH

  • 2:05 Hemophilia/Von Willebrand Disease | Larissa Bornikova, MD

  • 2:35 Combined Q&A | Larissa Bornikova, MD & Rachel Rosovsky, MD, MPH

  • 2:50 Thrombotic Thrombocytopenic Purpura (TTP) | Pavan Bendapudi, MD

  • 3:10 Heparin-Induced Thrombocytopenia (HIT) | Jonathan Carlson, MD, PhD

  • 3:30 Combined Q&A | Pavan Bendapudi, MD & Jonathan Carlson, MD, PhD

  • 3:45 PM Adjournment



Learning Objectives Upon completion of this activity, participants will be able to:

  1. Identify and initiate management for a wide spectrum of hematology diseases.

  2. Recognize emergent hematologic processes.

  3. Operate appropriate diagnostic studies and initiate therapy.



Accreditation In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statements

AMA PRA Category 1 Credits™ Mass General Brigham designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Mass General Brigham designates this activity for 7.00 ANCC contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants Mass General Brigham has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.


51 views0 comments

Recent Posts

See All

Cancer Equity Colloquium 2024

Now more than ever, the presence of social inequities in healthcare is evident. This two-day, hybrid event, the Cancer Equity Colloquium, will address the diverse issues that underlie cancer inequitie

Comments


bottom of page